Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding
The objective of this study was to assess the cost effectiveness of direct-acting oral anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a HAS-BLED score of 3.
Total costs (US$) in 2017 and quality-adjusted life-years were estimated over 20 years using a Markov model. A base-case analysis was conducted under a societal perspective, which included direct healthcare, non-healthcare and indirect costs in Thailand. Clinical events for warfarin and utilities were obtained from Thai patients whenever possible. The efficacy of direct-acting oral anticoagulants was derived from trial-based East Asian subgroups and adjusted for time in the target international normalized ratio range of warfarin.
In the base case, use of apixaban instead of warfarin incurred an additional cost of US$20,763 per quality-adjusted life-year gained. Substituting apixaban with rivaroxaban and rivaroxaban with high-dose edoxaban would incur an additional cost per quality-adjusted life-year by US$507 and US$434, respectively. Compared with warfarin, high-dose edoxaban had the lowest incremental cost-effectiveness ratio of US$9704/quality-adjusted life-year, followed by high-dose dabigatran (incremental cost-effectiveness ratio US$11,155/quality-adjusted life-year). The incremental cost-effectiveness ratios based on a payer perspective were similar. The incremental cost-effectiveness ratio was below Thailand’s cost-effectiveness threshold when high-dose dabigatran and edoxaban prices were reduced by 50%. Changes in key parameters had a minimal impact on incremental cost-effectiveness ratios.
For both societal and payer perspectives, high-dose edoxaban with a price below the country cost-effectiveness threshold should be the first anticoagulant option for Thai patients with non-valvular atrial fibrillation and a high risk of bleeding.
The authors thank Dr. Cynthia R. Gross and Dr. Jeffrey Roy Johns for providing editing assistance. The authors also thank four reviewers for valuable comments.
TR provided the study concept and design, and contributed to the analysis and interpretation of the data and drafting of the paper. CL provided the study concept and design, contributed to the analysis and interpretation of the data and drafting of the paper, and critically revised the paper for intellectual content. OW contributed to the analysis and interpretation of the data. PL and KS critically revised the paper for intellectual content. All authors were involved in the final approval of the version to be published and agree to be accountable for all aspects of the work.
This study was funded by the Faculty of Pharmaceutical Sciences, Khon Kaen University.
Compliance with Ethical Standards
Conflicts of interest
Thananan Rattanachotphanit, Chulaporn Limwattananon, Onanong Waleekhachonloet, Phumtham Limwattananon, and Kittisak Sawanyawisuth have no conflicts of interest that are directly relevant to the contents of this study.
All data generated or analyzed during this study are included in this published article and its Electronic Supplementary Material.
- 2.European Society of Cardiology. Atrial fibrillation 2016 (management of): ESC clinical practice guidelines. Available from: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management. Accessed 2 Dec 2016.
- 4.López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058. https://doi.org/10.1136/bmj.j5058.CrossRefGoogle Scholar
- 7.Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. J Med Econ. 2014;17:587–98.CrossRefGoogle Scholar
- 14.Hospodar AR, Smith KJ, Zhang Y, Hernandez I. Comparing the cost effectiveness of non-vitamin k antagonist oral anticoagulants with well-managed warfarin for stroke prevention in atrial fibrillation patients at high risk of bleeding. Am J Cardiovasc Drugs. 2018 May 9. https://doi.org/10.1007/s40256-018-0279-y. [Epub ahead of print].
- 20.Chaikledkaew U. Guidelines for health technology assessment in Thailand. 2nd ed. Nonthaburi: Wacharinprint; 2013.Google Scholar
- 22.Methavigul K, Boonyapisit W. Optimal INR level in Thai atrial fibrillation patients who were receiving warfarin for stroke prevention in Thailand. J Med Assoc Thail. 2014;97:1274–80.Google Scholar
- 26.Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.Google Scholar
- 28.Phrommintikul A, Detnuntarat P, Prasertwitayakij N, Wancharoen W. Prevalence of atrial fibrillation in Thai elderly. J Geriatr Cardiol. 2016;13:270–3.Google Scholar
- 29.Krittayaphong R, Winijkul A, Methavigul K, Wongtheptien W, Wongvipaporn C, Wisaratapong T, et al. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study. BMC Cardiovasc Disord. 2018;18:174. https://doi.org/10.1186/s12872-018-0911-4.CrossRefGoogle Scholar
- 30.Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Am Heart J. 2014;168:303–9.CrossRefGoogle Scholar
- 32.Yamashita T, Koretsune Y, Yang Y, Chen S, Chung N, Shimada YJ et al. Edoxaban vs. warfarin in East Asian patients with atrial fibrillation: an ENGAGE AF-TIMI 48 subanalysis. Circ J. 2016;80:860–9.Google Scholar
- 35.World Health Organization. Global health observatory data repository: life tables by country Thailand. http://apps.who.int/gho/data/?theme=main&vid=61640. Accessed 2 Dec 2016.
- 40.Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36(192–210):e20.Google Scholar
- 42.Riewpaiboon A. Standard cost lists for health technology assessment. 2010. http://www.hitap.net/costingmenu/. Accessed 9 Dec 2012.
- 44.Briggs AH, Claxton K, Schulpher MJ. Decision modeling for health economic evaluation. Oxford: Oxford University Press; 2006.Google Scholar